X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (633) 633
Publication (57) 57
Book Review (10) 10
Newsletter (9) 9
Book Chapter (4) 4
Book / eBook (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
radioimmunotherapy (406) 406
humans (369) 369
non-hodgkins-lymphoma (279) 279
oncology (268) 268
ibritumomab tiuxetan radioimmunotherapy (261) 261
antibodies, monoclonal - therapeutic use (218) 218
index medicus (205) 205
ibritumomab tiuxetan (203) 203
rituximab (195) 195
b-cell lymphoma (161) 161
follicular lymphoma (161) 161
hematology (156) 156
refractory low-grade (144) 144
radioimmunotherapy - methods (130) 130
radiology, nuclear medicine & medical imaging (124) 124
female (121) 121
male (119) 119
middle aged (113) 113
low-grade (112) 112
treatment outcome (110) 110
chemotherapy (104) 104
phase-ii trial (104) 104
aged (100) 100
immunotherapy (96) 96
lymphoma (96) 96
cancer (95) 95
anti-cd20 monoclonal-antibody (94) 94
adult (92) 92
lymphomas (92) 92
iodine i-131 tositumomab (90) 90
y-90 ibritumomab tiuxetan (90) 90
therapy (84) 84
non-hodgkin's lymphoma (76) 76
chronic lymphocytic-leukemia (74) 74
non-hodgkin's lymphomas (74) 74
yttrium radioisotopes - therapeutic use (73) 73
y-90-ibritumomab tiuxetan (72) 72
antineoplastic agents - therapeutic use (71) 71
lymphoma, non-hodgkin - radiotherapy (71) 71
care and treatment (69) 69
transplantation (67) 67
monoclonal antibodies (66) 66
trial (66) 66
zevalin (66) 66
animals (65) 65
stem-cell transplantation (64) 64
antibodies, monoclonal - adverse effects (61) 61
term-follow-up (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (56) 56
antibodies, monoclonal - administration & dosage (55) 55
i-131 tositumomab (54) 54
clinical trials as topic (53) 53
aged, 80 and over (49) 49
follow-up (49) 49
radiotherapy (49) 49
antibodies, monoclonal, murine-derived (48) 48
lymphoma, non-hodgkin - therapy (47) 47
pharmacology & pharmacy (47) 47
randomized controlled-trial (47) 47
antigens, cd20 - immunology (45) 45
dosimetry (45) 45
non-hodgkin lymphoma (45) 45
combined modality therapy (44) 44
lymphoma, non-hodgkin - drug therapy (43) 43
tositumomab (43) 43
lymphoma, b-cell - radiotherapy (42) 42
research (42) 42
health aspects (41) 41
medicine, research & experimental (41) 41
radiopharmaceuticals - therapeutic use (41) 41
bone-marrow-transplantation (40) 40
disease-free survival (40) 40
acute myeloid-leukemia (39) 39
high-dose therapy (39) 39
phase-ii (38) 38
immunology (37) 37
radioimmunotherapy - adverse effects (37) 37
y-ibritumomab tiuxetan (37) 37
monoclonal-antibody (35) 35
lymphoma, follicular - radiotherapy (34) 34
mice (34) 34
recurrence (34) 34
stem cells (34) 34
hematology, oncology and palliative medicine (32) 32
remission induction (32) 32
cd20 (30) 30
immunoconjugates - therapeutic use (30) 30
monoclonal antibody (30) 30
non-hodgkin-lymphoma (30) 30
safety (30) 30
chemotherapy plus rituximab (29) 29
prognosis (29) 29
progression-free survival (29) 29
high-dose chemotherapy (28) 28
lymphoma, follicular - therapy (28) 28
antibody (27) 27
article (26) 26
clinical trials (26) 26
dosage and administration (26) 26
hemic and lymphatic diseases (26) 26
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (621) 621
French (8) 8
German (8) 8
Spanish (4) 4
Japanese (3) 3
Czech (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 01/2014, Volume 32, Issue 3, pp. 212 - 212
Purpose We report an international, multicenter phase II trial to evaluate the efficacy and toxicity of fractionated Y-90-ibritumomab tiuxetan (Y-90-IT) as... 
TRIAL | 1ST-LINE TREATMENT | B-CELL LYMPHOMA | ONCOLOGY | NON-HODGKINS-LYMPHOMA | FOLLOW-UP | LOW-GRADE | MONOCLONAL-ANTIBODY | YTTRIUM-90 IBRITUMOMAB TIUXETAN | CHEMOTHERAPY PLUS RITUXIMAB | DURABLE RESPONSES
Journal Article
Oncology, ISSN 0030-2414, 04/2018, Volume 94, Issue 5, pp. 274 - 280
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 03/2003, Volume 44, Issue 3, pp. 465 - 474
Ibritumomab tiuxetan is an ant-CD20 murine IgG1 K monoclonal antibody (ibritumomab) conjugated to the linker-chelator tiuxetan, which securely chelates In-111... 
ANTIBODIES | radioimmunotherapy | dosimetry | Y-90-ibritumomab tiuxetan | IDEC-Y2B8 RADIOIMMUNOTHERAPY | IBRITUMOMAB TIUXETAN | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | rituximab | BONE-MARROW DOSIMETRY
Journal Article
SCIENTIFIC WORLD JOURNAL, ISSN 1537-744X, 2014
Objective. To elucidate the time course of tumor metabolism during the first 3 months after Y-90-ibritumomab tiuxetan radioimmunotherapy (RIT) in patients with... 
FDG-PET | B-CELL LYMPHOMA | POSITRON-EMISSION-TOMOGRAPHY | THERAPY | RESPONSE CRITERIA | RITUXIMAB | MULTIDISCIPLINARY SCIENCES | EARLY INTERIM | NON-HODGKINS-LYMPHOMA | IBRITUMOMAB TIUXETAN | CHEMOTHERAPY
Journal Article
CANCER, ISSN 0008-543X, 07/2006, Volume 107, Issue 2, pp. 433 - 438
BACKGROUND. Non-Hodgkin lymphomas (NHL) are radiosensitive tumors. Recent trials have demonstrated the effectiveness of beta irradiation delivered by... 
NUDE-MICE | radioimmunotherapy | lymphoma | STAGE-I | RADIORESISTANT | IRRADIATION | B-CELL LYMPHOMA | RADIORESPONSIVENESS | ONCOLOGY | radiation | tumor response | LOW-GRADE | RADIOTHERAPY | IBRITUMOMAB TIUXETAN | HUMAN-TUMORS
Journal Article
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 07/2013, Volume 54, Issue 7, pp. 1045 - 1052
The aim of this study was to determine the maximum tolerated dose (MTD) and to explore the clinical response to Lu-177-DOTA-rituximab in the treatment of... 
radioimmunotherapy | lymphoma | IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY | ANTI-CD20 MONOCLONAL-ANTIBODY | THERAPY | REFRACTORY LOW-GRADE | NON-HODGKINS-LYMPHOMA | IDEC-Y2B8 RADIOIMMUNOTHERAPY | Lu-177 | RADIOTHERAPY | IODINE I-131 TOSITUMOMAB | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | rituximab
Journal Article
EUROPEAN JOURNAL OF HAEMATOLOGY, ISSN 0902-4441, 10/2018, Volume 101, Issue 4, pp. 514 - 521
Background: Follicular lymphoma (FL) is the most frequent indolent lymphoma sub-type in adults. Maintenance therapy with rituximab is frequently applied to FL... 
1ST-LINE TREATMENT | follicular lymphoma | IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY | FOLLOW-UP | Y-90-IBRITUMOMAB TIUXETAN | Y-90-ibritumomab-tiuxetan | ADVANCED-STAGE | PHASE-II TRIAL | NHL | INTERNATIONAL PROGNOSTIC INDEX | NON-HODGKINS-LYMPHOMA | LOW-GRADE | HEMATOLOGY | rituximab | RITUXIMAB MAINTENANCE
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.